← Leaderboards
William Walton Stoops
University Of Kentucky
$15,269,484
Attributed
$17,361,420
Total exposure
19
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,361,420 · 19
By mechanism
R01$11,092,874 · 9
R21$2,246,541 · 6
R33$1,854,763 · 1
TL1$999,061 · 1
T32$927,831 · 1
R13$240,350 · 1
Top collaborators
- Cassandra D Gipson-Reichardt5 shared
- Craig R Rush3 shared
- Lauren Whitehurst2 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Sharon L. Walsh$101,480,172
- Cassandra D Gipson-Reichardt$6,257,792
- Craig R Rush$27,535,139
- Chana K. Akins$1,704,815
- Emily D. Klein$31,381
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DosePharmaceutical PreparationsCocaineLaboratoriesPlacebosCocaine UseMaintenancePublic HealthPre-ClinicalSelf AdministrationMeetingsPhysiologicalAbstinenceAttenuatedAmericanBehaviorOralClinical TrialsChronicRandomizedReportingDrug UsageAreaMotivation
Grant awards (42)
Advancing Non-Abstinence Outcomes in the Treatment of Methamphetamine Use Disorder$731,997
R01 · FY2025 · DA · contact PI
Advancing Troriluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study$634,048
R01 · FY2025 · DA · contact PI
Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study with Pentoxifylline$620,383
R01 · FY2025 · DA · contact PI
NRSA Training Core$512,842
TL1 · FY2025 · TR · contact PI
Influence of Orexin Antagonism on Motivation for Alcohol$511,216
R01 · FY2025 · AA · contact PI
Research Training in Drug Abuse Behavior$372,109
T32 · FY2025 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$630,599
R33 · FY2024 · DA
Influence of Orexin Antagonism on Motivation for Alcohol$526,984
R01 · FY2024 · AA · contact PI
NRSA Training Core$486,219
TL1 · FY2024 · TR · contact PI
Research Training in Drug Abuse Behavior$201,327
T32 · FY2024 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$609,607
R33 · FY2023 · DA
Research Training in Drug Abuse Behavior$354,395
T32 · FY2023 · DA
Influence of 5-HT1b Activation on the Abuse Related Effects of Cocaine$660,131
R01 · FY2022 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$614,557
R33 · FY2022 · DA
Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use$574,367
R01 · FY2022 · DA · contact PI
Scientific Conferences for The College on Problems of Drug Dependence (CPDD)$95,000
R13 · FY2022 · DA · contact PI
Influence of 5-HT1b Activation on the Abuse Related Effects of Cocaine$620,403
R01 · FY2021 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$188,617
R21 · FY2021 · DA
Scientific Conferences for The College on Problems of Drug Dependence (CPDD)$50,350
R13 · FY2021 · DA · contact PI
Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use$574,367
R01 · FY2020 · DA · contact PI
Influence of Orexin Antagonism on Motivation for Cocaine$556,032
R01 · FY2020 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$213,600
R21 · FY2020 · DA
Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use$574,367
R01 · FY2019 · DA · contact PI
Influence of Orexin Antagonism on Motivation for Cocaine$550,763
R01 · FY2019 · DA · contact PI
Annual Meeting of the College on Problems of Drug Dependence$95,000
R13 · FY2019 · DA · contact PI
Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use$574,367
R01 · FY2018 · DA · contact PI
A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder$168,553
R21 · FY2018 · AA · contact PI
Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use$625,386
R01 · FY2017 · DA · contact PI
Selective Monoamine Release as a Treatment for Cocaine Use Disorders$560,020
R01 · FY2017 · DA · contact PI
A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder$206,932
R21 · FY2017 · AA · contact PI
Selective Monoamine Release as a Treatment for Cocaine Use Disorders$526,586
R01 · FY2015 · DA · contact PI
Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis$167,595
R21 · FY2015 · DA · contact PI
Selective Monoamine Release as a Treatment for Cocaine Use Disorders$500,484
R01 · FY2014 · DA · contact PI
Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis$208,229
R21 · FY2014 · DA · contact PI
A Human Laboratory Study to Investigate Buspirone for Cocaine Use Disorders$195,374
R21 · FY2013 · DA · contact PI
A Human Laboratory Study to Investigate Buspirone for Cocaine Use Disorders$167,561
R21 · FY2012 · DA · contact PI
Neuropharmacology of Tramadol: Clinical Efficacy and Abuse Potential$589,457
R01 · FY2010 · DA · contact PI
Neuropharmacology of Tramadol: Clinical Efficacy and Abuse Potential$581,516
R01 · FY2009 · DA · contact PI
Human Lab Model of Behavioral/Pharmacological Treatment for Cocaine Dependence$219,750
R21 · FY2009 · DA · contact PI
Human Lab Model of Behavioral/Pharmacological Treatment for Cocaine Dependence$183,125
R21 · FY2008 · DA · contact PI
Internet Based Voucher Reinforcement for Smoking Cessation$149,225
R21 · FY2008 · CA · contact PI
Internet Based Voucher Reinforcement for Smoking Cessation$177,980
R21 · FY2007 · CA · contact PI